466 related articles for article (PubMed ID: 36728908)
21. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
23. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
Wang Y; Yang N; Zhang Y; Li Li ; Han R; Zhu M; Feng M; Chen H; Lizaso A; Qin T; Liu X; He Y
J Thorac Oncol; 2020 Aug; 15(8):1369-1375. PubMed ID: 32353596
[TBL] [Abstract][Full Text] [Related]
24. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
[TBL] [Abstract][Full Text] [Related]
25. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
26. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell
Lung Cancer Patients with Acquired EGFR T790M Mutation].
Gu Y; Tian X; Wang R; Li X; Qian K; Li Y; Nong J
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):843-851. PubMed ID: 36617470
[TBL] [Abstract][Full Text] [Related]
28. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
[TBL] [Abstract][Full Text] [Related]
29. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.
Nie K; Jiang H; Zhang C; Geng C; Xu X; Zhang L; Zhang H; Zhang Z; Lan K; Ji Y
Biomed Res Int; 2018; 2018():9010353. PubMed ID: 29713646
[TBL] [Abstract][Full Text] [Related]
30. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
32. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
[TBL] [Abstract][Full Text] [Related]
33. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
35. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
36. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
37. Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.
Wang Y; Zhang H; Zou Y; Ren X; Wang H; Bai R; Xu K; Xu Y; Zhang Z
Asia Pac J Clin Oncol; 2023 Dec; 19(6):715-722. PubMed ID: 36756895
[TBL] [Abstract][Full Text] [Related]
38. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH
Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
40. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
